Cell and gene therapies are at an inflection point, as increasing quantities of clinical data highlight both their potential and their challenges before they can become mainstream therapies treating genetic diseases. Chief among them, according to panelists at The Future of Gene Therapies session at BIO-Europe 2021 – Digital, October 25-28, are safety and delivery. READ MORE
Leaders in the fields of RNA and cardiovascular disease join HAYA to advance its pipeline of therapeutics targeting long non-coding RNAs LAUSANNE, Switzerland — HAYA Therapeutics, SA, a company developing precision medicines that target tissue and cell-specific long non-coding RNAs (lncRNAs), today announced the formation and members of its Scientific Advisory Board (SAB). The group …
HAYA Therapeutics Announces Scientific Advisory Board Read More »
When Samir Ounzian left London a decade ago to study a little-understood branch of the genome at a Swiss lab, he wasn’t sure what he would find. Known as long-non-coding RNA, these sections were translated into looping rings of RNA — hence the name — but didn’t actually translate into proteins, and no one was …
A new RNA startup looks to reimagine heart treatments, with eyes set on Entresto Read More »
Swiss precision medicine biotech Haya Therapeutics is coming out of stealth today with nearly $20 million, or CHF 18 million, in seed funding to boost its anti-fibrotic therapies. The preclinical startup’s seed round was led by Broadview Ventures and included participation from Apollo Health Ventures, BERNINA BioInvest, 4See Ventures, Schroder Adveq and Viva BioInnovator. READ MORE
HAYA Therapeutics, a company developing precision medicines that target tissue and cell-specific long non-coding RNAs (lncRNAs), closed its CHF 18 million Seed round. The financing was led by Broadview Ventures, with participation from Apollo Health Ventures, BERNINA BioInvest, 4See Ventures, Schroder Adveq, and Viva BioInnovator. HAYA Therapeutics was a Venture Kick winner and a Venture …
Two different companies, cardiac fibrosis RNA company HAYA Therapeutics and COVID-19 bispecific player RenBio, launched today with funding rounds designed to push them toward the clinic. New York-based RenBio announced a $24 million series A round, led by Ruentex Group, to move its lead bispecific antibody into phase 1/2 trials by the end of the year. …